Key Takeaways
Synthetic chromosome technologies expand genomic medicine beyond the limits of conventional gene delivery by enabling the introduction of megabase-scale DNA constructs capable of carrying full gene loci and regulatory elements.
Human artificial chromosomes (HACs) function as stable episomal vectors that can maintain large genetic payloads without integrating into the host genome, reducing the risk of insertional mutagenesis associated with some traditional gene therapy platforms.
Microcell-mediated chromosome transfer remains the primary method for introducing artificial chromosomes into cells, but its technical complexity and limited efficiency represent major barriers to clinical translation.
Translating synthetic chromosome therapeutics into clinical applications will depend on advances in large-DNA assembly, chromosome delivery technologies, and scalable cell-therapy manufacturing infrastructure.
Modern gene therapy has transformed the treatment landscape for a growing number of genetic disorders, but the technologies used to deliver therapeutic DNA impose important constraints on what can be accomplished. Most current approaches rely on viral vectors or plasmid-based systems to introduce therapeutic genes into cells. While these tools have enabled the first generation of gene therapies, their design reflects compromises that limit the size and complexity of the genetic material that can be delivered.
One challenge arises from how many delivery systems interact with the host genome. Some vectors integrate genetic material into chromosomal DNA, which can create long-term expression but also introduces risks associated with random insertion. When exogenous DNA integrates near regulatory elements or proto-oncogenes, it can disrupt normal gene regulation or activate oncogenic pathways. These concerns have shaped the design of modern gene-delivery platforms and contributed to ongoing efforts to develop systems that avoid uncontrolled genomic integration.
Another limitation involves the scale of genetic payloads that current vectors can accommodate. Many genes function within complex regulatory architectures that include promoters, enhancers, and other control elements located outside the coding sequence itself. Delivering only the coding region of a gene may not reproduce its natural regulation, particularly when expression must be tightly controlled across different cell types or developmental stages. For this reason, therapeutic strategies often require delivery of larger genomic fragments that include both the gene and its regulatory context.
These challenges become more pronounced for diseases associated with very large genes or gene clusters. Some genomic loci extend hundreds of kilobases or more and include multiple regulatory elements that influence expression. Conventional delivery platforms struggle to accommodate sequences of this scale, forcing researchers to rely on truncated constructs or alternative engineering strategies that may not fully replicate endogenous gene function.
Human artificial chromosomes (HACs) were developed in part to address these limitations. Instead of delivering isolated DNA fragments that integrate into host chromosomes, HAC systems introduce independent chromosomal structures capable of carrying large genomic regions while remaining separate from the host genome. Because they function as autonomous episomes and segregate during cell division, artificial chromosomes can support stable expression of large gene loci without the risks associated with random genomic integration.1
The concept of payload scale therefore represents a fundamental constraint in genomic medicine. As researchers attempt to treat increasingly complex genetic diseases, the ability to deliver larger and more sophisticated genomic constructs becomes a critical design parameter. Artificial chromosome platforms illustrate one approach to expanding that payload capacity, enabling therapeutic strategies that operate at the scale of entire genomic loci rather than individual coding sequences.
HACs were developed to expand the scale at which genetic material can be delivered and maintained in mammalian cells. Unlike conventional gene delivery vectors, which typically carry relatively small DNA fragments, HACs are designed to function as independent chromosomal structures capable of accommodating extremely large genomic sequences. Experimental systems have demonstrated that artificial chromosomes can carry DNA inserts exceeding one megabase in length, providing a payload capacity far beyond that of most commonly used gene-delivery platforms.1
Artificial chromosomes are engineered as exogenous mini-chromosomes that replicate and segregate alongside the host cell’s natural chromosomes. Their structure includes key chromosomal elements, such as centromeres, which allow the artificial chromosome to be maintained during cell division. Two general strategies have been used to construct these systems. In top-down approaches, segments of natural chromosomes are modified or truncated to generate stable artificial chromosome platforms. Bottom-up approaches, by contrast, assemble artificial chromosomes from defined DNA components, including synthetic centromeric sequences that enable proper chromosomal behavior in the cell.1
The resulting vectors possess several functional properties that distinguish them from conventional gene-delivery technologies. HACs remain episomal, meaning they exist as separate chromosomes rather than integrating into host DNA. This autonomy allows them to be maintained stably across many rounds of cell division while avoiding disruptions to the host genome. Artificial chromosomes also provide unusually large genetic capacity, enabling the introduction of complete gene loci along with their surrounding regulatory elements. Because these loci retain the promoters, enhancers, and other genomic features that control gene expression, they can more closely reproduce physiological patterns of regulation than truncated gene constructs delivered by smaller vectors.
These characteristics have important implications for therapeutic applications. Many disease-associated genes are large or require complex regulatory architecture to function properly. Artificial chromosome vectors offer a way to deliver full-length genes together with the regulatory elements needed to support normal expression. At the same time, their episomal nature reduces the risk that therapeutic DNA will disrupt endogenous genes through random insertion. Artificial chromosomes are potentially one of the few platforms capable of delivering genomic payloads at the megabase scale while maintaining long-term stability inside mammalian cells.
The trajectory of genome engineering has steadily expanded the scale at which genetic material can be manipulated. Early molecular biology relied on plasmid vectors capable of introducing small DNA fragments into cells. Viral vectors later enabled more efficient delivery of therapeutic genes and laid the foundation for modern gene therapy. The development of programmable genome-editing systems introduced the ability to modify specific loci within chromosomes with high precision. More recently, advances in chromosome engineering have begun to extend these capabilities further, enabling the manipulation of genomic structures at the scale of entire chromosomes rather than individual genes.2
This progression reflects a gradual shift in how genetic interventions are conceived. Early approaches focused on inserting or correcting single coding sequences. Genome-editing technologies expanded the ability to modify specific loci within the native genome. Artificial chromosome systems take a different approach by introducing new chromosomal structures capable of carrying large genomic regions and functioning alongside endogenous chromosomes. In doing so, they expand the design space of genomic engineering from gene-level modifications to the introduction of entirely new genetic platforms within the cell.
Artificial chromosomes enable researchers to manipulate genomic structures that would be difficult or impossible to modify using conventional gene-editing tools. Because they can accommodate very large DNA segments, these systems provide a framework for studying how genes function within their natural genomic context. Researchers have used artificial chromosome platforms to investigate gene regulation, chromatin organization, and other processes that depend on interactions across extended regions of DNA.2 In this way, chromosome engineering has become both a research tool for studying genome biology and a potential platform for therapeutic innovation.
Within the broader field of synthetic biology, artificial chromosomes also provide a foundation for constructing large genetic systems that operate within mammalian cells. Their capacity to carry extensive genomic regions allows the introduction of multigene pathways or coordinated regulatory networks. These capabilities open the possibility of engineering cells with more sophisticated genetic programs than those typically achieved through conventional gene delivery approaches. By enabling the integration of multiple genes and regulatory elements within a single chromosomal platform, artificial chromosomes expand the potential scope of cellular engineering strategies aimed at therapeutic applications.3
The large payload capacity of HACs opens therapeutic possibilities that are difficult to achieve with conventional gene-delivery systems. Because these vectors can accommodate large genomic regions and maintain them as independent chromosomal structures, they provide a framework for delivering genetic material that exceeds the capacity of most commonly used vectors. For this reason, HAC platforms have been explored as tools for both gene therapy and cell therapy applications in which stable expression of large or complex genetic constructs is required.
One of the clearest therapeutic motivations for artificial chromosome technology involves diseases caused by defects in large genes or genomic regions that include extensive regulatory architecture. In many cases, simply delivering the coding sequence of a gene is not sufficient to restore normal function. Proper expression often depends on regulatory elements located across a broader genomic locus, including promoters, enhancers, and other control sequences that coordinate transcription.
Artificial chromosome vectors make it possible to introduce these larger genomic regions intact. Because HACs can carry extensive DNA sequences together with their associated regulatory elements, they can support gene expression patterns that more closely resemble those found in natural genomic contexts. Instead of relying on truncated constructs or synthetic promoters, artificial chromosome systems allow therapeutic genes to be delivered together with the regulatory architecture that governs their physiological activity.
Muscular dystrophies illustrate why this capability matters. Some of the genes associated with these disorders are unusually large and contain extensive regulatory sequences that influence expression across muscle tissues. Delivering the entire genomic locus may help preserve the mechanisms needed for correct expression and tissue specificity. Similar challenges arise in certain metabolic disorders and developmental diseases in which gene expression must be tightly controlled across multiple tissues or stages of development. In such cases, the ability to deliver a complete gene locus rather than an isolated coding sequence may be critical for achieving
Artificial chromosomes also enable therapeutic strategies that extend beyond replacing defective genes. Their large carrying capacity allows researchers to introduce coordinated sets of genes into cells, creating the possibility of engineering complex genetic programs. In contrast to traditional gene therapy approaches that deliver a single gene or a small number of genes, HAC vectors can accommodate multi-gene regulatory networks that operate together within the same chromosomal structure.
This capability opens the door to cellular engineering strategies that require multiple genetic components working in concert. For example, engineered immune cells could potentially be programmed with additional regulatory circuits that control activation, persistence, or metabolic behavior. Artificial chromosomes may also support the introduction of synthetic metabolic pathways or other multigene systems designed to produce therapeutic molecules or modify cellular functions.
Because these systems are maintained as independent chromosomes rather than integrated into host DNA, they provide a flexible platform for building complex genetic architectures without disrupting the endogenous genome.
A more speculative but conceptually important application of artificial chromosome technology involves the transfer of entire chromosomes between cells. Techniques such as microcell-mediated chromosome transfer (MMCT) allow individual chromosomes to be isolated from donor cells and introduced into recipient cells through specialized cell-fusion procedures.4
Although these approaches remain primarily experimental, they demonstrate that chromosomes themselves can function as transferable genetic units. In principle, chromosome transfer technologies could eventually allow researchers to replace or supplement defective chromosomes with engineered versions carrying functional genetic material. Such strategies would represent a form of genomic correction operating at the scale of entire chromosomes rather than individual genes.
While these concepts remain at an early stage of development, they illustrate how artificial chromosome platforms expand the scope of therapeutic genome engineering. By enabling the delivery of large genomic regions and coordinated gene systems, synthetic chromosome technologies point toward new approaches for treating diseases that require more than conventional gene replacement strategies.2
Despite the conceptual appeal of synthetic chromosome therapeutics, delivering these large genetic structures into cells remains one of the most significant technical challenges in the field. Human artificial chromosomes can be constructed and engineered in donor cell lines, but transferring them into the desired recipient cells requires specialized techniques capable of moving chromosome-scale DNA structures between cells. Among the methods developed for this purpose, MMCT has become the most widely used approach for introducing artificial chromosomes into mammalian cells.4
MMCT was originally developed as a tool for studying chromosome function and gene mapping, but it has since become central to artificial chromosome engineering. The technique exploits the ability of cells to form micronuclei — small, membrane-bound structures containing individual chromosomes — under certain experimental conditions. These micronuclei can be isolated as microcells and fused with recipient cells, allowing the enclosed chromosome to enter a new cellular environment. Once transferred, cells that successfully acquire the chromosome are identified and expanded through selection procedures.5
In practice, the MMCT workflow involves several stages. First, donor cells containing the chromosome of interest are treated with agents that promote micronucleation, generating microcells that encapsulate individual chromosomes. These microcells are then physically separated from the donor cells and fused with recipient cells using chemical or viral fusion agents. Finally, recipient cells are screened to identify those that have successfully incorporated the transferred chromosome.4 Through this process, artificial chromosomes engineered in one cell line can be introduced into entirely different cellular contexts.
The range of chromosomes that can be transferred using MMCT is remarkably broad. Researchers have used the method to introduce artificial chromosomes designed specifically for gene delivery as well as natural human chromosomes isolated from donor cells. Artificial chromosomes used in experimental systems often measure several megabases in size, while natural human chromosomes transferred through MMCT can range from roughly 45 to more than 150 megabases, depending on the chromosome involved.6
Despite its utility, MMCT remains technically demanding and is widely regarded as one of the main bottlenecks in artificial chromosome research. Transfer efficiencies can be low, and the procedure requires specialized laboratory expertise and equipment. Multiple steps, including micronucleus induction, microcell isolation, and cell fusion, must be carefully coordinated to achieve successful chromosome transfer. These challenges limit the scalability of current approaches and highlight why chromosome delivery remains a central obstacle in translating synthetic chromosome technologies into therapeutic platforms.
While artificial chromosome systems demonstrate compelling capabilities at the laboratory scale, translating them into therapeutic platforms introduces substantial manufacturing and process-development challenges. The engineering steps required to construct, load, and deliver artificial chromosomes are complex and remain largely confined to specialized research environments. Among these steps, the transfer of artificial chromosomes between cells is widely regarded as one of the most technically demanding stages in the overall workflow.4
Artificial chromosome construction begins with the assembly of large genomic DNA segments into structures capable of behaving as functional chromosomes. These constructs must include essential chromosomal features, such as centromeres, that enable proper replication and segregation during cell division. Building these structures often requires cloning and assembling large DNA fragments along with the chromosomal elements needed for stability and inheritance.
These workflows can involve either modification of natural chromosomes or construction of synthetic chromosomal elements. In both cases, the engineering process typically requires multiple rounds of cloning, recombination, and verification to ensure that the resulting artificial chromosome behaves correctly in mammalian cells. The scale of the DNA involved and the complexity of chromosomal architecture make these procedures considerably more labor-intensive than the preparation of conventional gene-delivery vectors.
Once an artificial chromosome platform has been constructed, therapeutic genes must be inserted into the chromosome before transfer into recipient cells. This process frequently relies on recombination systems that enable targeted insertion of genetic material into predefined sites within the artificial chromosome. These systems allow researchers to add genes or regulatory elements while preserving the structural integrity of the chromosome.7
Because artificial chromosomes can accommodate large genomic segments, this engineering stage may involve loading entire gene loci or multigene constructs. Each additional genetic element introduces further complexity, requiring validation to confirm that the inserted sequences are correctly integrated and expressed. The engineering process therefore resembles a multi-step genomic assembly pipeline rather than a simple vector-cloning workflow.
After engineering is complete, the artificial chromosome must be transferred from the donor cell line in which it was constructed to the therapeutic cell type intended for treatment. At present, this step typically relies on microcell-mediated chromosome transfer or related techniques. These procedures require donor cells containing the engineered chromosome, induction of micronuclei that isolate individual chromosomes, and fusion of the resulting microcells with recipient cells.4
The multi-stage nature of this process introduces practical constraints for manufacturing. Donor cell lines must be maintained and characterized, microcells must be generated and isolated, and recipient cells must be screened to confirm successful chromosome transfer. Each step introduces opportunities for variability and requires specialized technical expertise.
Because artificial chromosome delivery currently relies on cell-based transfer methods, most therapeutic strategies built around HAC technology assume an ex vivo workflow. In this model, patient-derived cells are isolated, engineered with artificial chromosomes in a controlled laboratory environment, and then returned to the patient following expansion and quality control testing.8
This approach parallels the manufacturing strategies used for several existing advanced therapies. Cell therapies, such as CAR-T treatments, follow a similar sequence of cell isolation, genetic engineering, expansion, and reinfusion. Artificial chromosome therapeutics could therefore fit conceptually within the same general framework of ex vivo cell engineering, although the complexity of chromosome manipulation introduces additional technical hurdles.
Moving artificial chromosome technologies from laboratory demonstrations to scalable therapeutic platforms would require significant advances in several enabling technologies. Improvements in large-DNA assembly methods would be necessary to streamline chromosome construction. More efficient chromosome delivery systems would be required to replace or enhance existing transfer techniques. Finally, robust cell-engineering and manufacturing infrastructure would be needed to support the complex workflows associated with chromosome-scale genetic manipulation.
These challenges illustrate why synthetic chromosome therapeutics remain largely experimental despite their conceptual advantages. The biological feasibility of artificial chromosomes has been demonstrated in numerous research settings, but translating these systems into practical therapeutic products will depend on solving engineering and manufacturing problems that extend well beyond the initial chromosome design stage.
The capabilities of the synthetic chromosome therapeutics systems suggest a potential platform for delivering genetic material at a scale that has historically been inaccessible to therapeutic technologies. Artificial chromosomes can accommodate large DNA inserts and maintain them as stable episomal elements within cells, enabling the expression of genes and regulatory elements across extended genomic regions. This capacity makes it possible to introduce multigene systems or complex regulatory programs within a single chromosomal construct, opening new possibilities for engineering cellular functions that depend on coordinated genetic activity.
Despite this promise, artificial chromosome therapeutics remain at an early stage of translational development. Several technical challenges continue to limit their practical application. Efficient delivery of artificial chromosomes into therapeutic cell types remains difficult, and existing transfer methods require specialized laboratory workflows that are not easily scaled. Chromosome construction and engineering processes also remain labor-intensive, requiring multiple stages of DNA assembly and validation before therapeutic constructs can be introduced into target cells.
These challenges highlight the gap that still exists between laboratory demonstrations and clinical translation. While artificial chromosome systems have been successfully engineered and transferred between cell lines in research settings, transforming these techniques into scalable therapeutic manufacturing platforms will require advances in chromosome assembly technologies, delivery methods, and cell-engineering infrastructure.
Even so, the conceptual implications of synthetic chromosome systems are significant. By enabling the delivery of large genomic regions and coordinated gene networks, these technologies point toward a future in which therapeutic interventions operate at the level of entire genomic pathways rather than individual genes. As genome engineering continues to evolve, artificial chromosomes may represent one of the clearest examples of how the scale of genetic medicine is expanding from gene replacement toward the broader engineering of cellular genomes.
1. Moralli, Daniela, and Zoi L Monaco. “Gene expressing human artificial chromosome vectors: Advantages and challenges for gene therapy.” Exp. Cell Res. 390: 11931 (2020).
2. Kouprina, Natalay, et al. “A new generation of human artificial chromosomes for functional genomics and gene therapy.” Cell Mol. Life Sci. 70: 1135–1148 (2012).
3. Martella, Andrea, et al. “Mammalian Synthetic Biology: Time for Big MACs.” ACY Synth. Biol. 5: 1040–1049 (2016).
4. Suzuki, Teruhiko, et al. “Current advances in microcell-mediated chromosome transfer technology and its applications.” Exp. Cell Res. 390: 111915 (2020).
5. Doherty, Aideen MO, and Elizabeth MC Fisher. “Microcell-mediated chromosome transfer (MMCT): small cells with huge potential.” Mamm. Genome. 14: 582–592 (2003).
6. Uno, Narumi, et al. “Microcell-mediated chromosome transfer between non-identical human iPSCs.” Mol. Ther. Nucleic Acids. 35: 102382 (2024).
7. Liskovykh, Mikhail, Vladimir Larionov, and Natalay Kouprina. “Highly Efficient Microcell-Mediated Transfer of HACs Containing a Genomic Region of Interest into Mammalian Cells.” Curr. Protoc. 1: e236 (2021).
8. Ponomartsev, Sergey V, et al. “Human AlphoidtetO Artificial Chromosome as a Gene Therapy Vector for the Developing Hemophilia A Model in Mice.” Cells. 9: 879 (2020).
